Simplex Trading LLC bought a new stake in shares of DBV Technologies SA – (NASDAQ:DBVT) during the first quarter, Holdings Channel reports. The fund bought 14,949 shares of the company’s stock, valued at approximately $526,000.

A number of other hedge funds also recently made changes to their positions in the stock. TD Asset Management Inc. purchased a new position in shares of DBV Technologies SA – during the third quarter worth about $272,000. Castleark Management LLC raised its position in DBV Technologies SA – by 136.9% in the fourth quarter. Castleark Management LLC now owns 9,690 shares of the company’s stock worth $340,000 after buying an additional 5,600 shares during the last quarter. Sectoral Asset Management Inc bought a new position in DBV Technologies SA – during the third quarter worth $1,428,000. Norges Bank bought a new position in DBV Technologies SA – during the fourth quarter worth $1,757,000. Finally, OLD Mission Capital LLC bought a new position in DBV Technologies SA – during the third quarter worth $2,207,000. 48.96% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for DBV Technologies SA - (NASDAQ:DBVT)

Shares of DBV Technologies SA – (NASDAQ:DBVT) traded down 1.39% during trading on Friday, hitting $32.62. The company had a trading volume of 30,791 shares. The firm’s market capitalization is $1.50 billion. The stock’s 50-day moving average is $34.77 and its 200 day moving average is $35.30. DBV Technologies SA – has a 52-week low of $27.02 and a 52-week high of $37.98.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Financial Market News and is owned by of Financial Market News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.financial-market-news.com/2017/04/21/simplex-trading-llc-buys-new-position-in-dbv-technologies-sa-dbvt.html.

A number of equities analysts have weighed in on DBVT shares. Zacks Investment Research lowered DBV Technologies SA – from a “buy” rating to a “hold” rating in a research note on Tuesday, January 17th. Natixis upgraded DBV Technologies SA – from a “neutral” rating to a “buy” rating in a research note on Friday, February 17th. Leerink Swann reiterated an “outperform” rating on shares of DBV Technologies SA – in a research note on Wednesday, March 15th. Jefferies Group LLC reiterated a “buy” rating and set a $47.00 price objective on shares of DBV Technologies SA – in a research note on Thursday, March 16th. Finally, Societe Generale upgraded DBV Technologies SA – from a “hold” rating to a “buy” rating in a research note on Thursday, March 16th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $46.50.

DBV Technologies SA – Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV Technologies SA – (NASDAQ:DBVT).

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.